Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viking Therapeutics

40.60
+2.837.49%
Pre-market: 42.211.61+3.97%07:46 EST
Volume:5.50M
Turnover:217.40M
Market Cap:4.59B
PE:-19.16
High:40.69
Open:37.66
Low:37.06
Close:37.77
52wk High:62.50
52wk Low:18.92
Shares:113.04M
Float Shares:109.98M
Volume Ratio:1.14
T/O Rate:5.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1195
EPS(LYR):-1.0085
ROE:-29.23%
ROA:-20.48%
PB:6.44
PE(LYR):-40.26

Loading ...

Viking Therapeutics Stock (VKTX) Jumps on Obesity Drug. Next Big Pharma Target?

TIPRANKS
·
Yesterday

Viking Therapeutics (VKTX): Evaluating Valuation After New Obesity Drug Data Spurs Fresh Interest

Simply Wall St.
·
Nov 08

Viking Therapeutics’ VK2735: A Promising Step Forward in Metabolic Disease Treatment Justifying a Buy Rating

TIPRANKS
·
Nov 08

Promising Potential of Viking Therapeutics’ VK2735: A Buy Rating Justified by Efficacy in Weight Loss and Metabolic Health

TIPRANKS
·
Nov 07

BRIEF-Viking Therapeutics Highlights Clinical Data From VK2735 Obesity Program In Presentation At ObesityWeek 2025

Reuters
·
Nov 06

Viking Therapeutics Highlights Clinical Data From Vk2735 Obesity Program in Presentation at Obesityweek® 2025

THOMSON REUTERS
·
Nov 06

Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain

Benzinga_recent_news
·
Nov 05

Jim Cramer Says 'Take A Pass' On This Tech Stock, Won't Go Near Oils

Benzinga
·
Nov 05

Viking Therapeutics (VKTX) Gets a Buy from BTIG

TIPRANKS
·
Oct 31

Metsera the US obesity biotech at centre of Novo, Pfizer bidding war

Reuters
·
Oct 31

Viking Therapeutics Showcases VK2735 Obesity Clinical Data at ObesityWeek 2025

Reuters
·
Oct 30

Canaccord Genuity Initiates Viking Therapeutics at Buy With $106 Price Target

MT Newswires Live
·
Oct 29

Viking Therapeutics Initiated at Buy by Canaccord Genuity

Dow Jones
·
Oct 29

Canaccord starts Viking Therapeutics with Buy on obesity potential

TIPRANKS
·
Oct 29

Viking Therapeutics Executives Unload Massive Stock Holdings!

TIPRANKS
·
Oct 29

Viking Therapeutics’ VK2735 Study: A Potential Game-Changer for Weight Management in Type 2 Diabetes

TIPRANKS
·
Oct 28

Viking Therapeutics price target lowered to $75 from $80 at JPMorgan

TIPRANKS
·
Oct 24

Viking Therapeutics (VKTX) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Oct 24

Viking Therapeutics Navigates Regulatory Risks Amid U.S. Policy Shifts

TIPRANKS
·
Oct 24

Viking Therapeutics Inc : JP Morgan Cuts Target Price to $75 From $80

THOMSON REUTERS
·
Oct 24